Question 1

What is Ivabradine?

Accepted Answer

Ivabradine is a medication classified as a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker. It works by slowing the heart's natural pacemaker, which reduces the heart rate.

By lowering the number of beats per minute, the medication helps the heart function more effectively. It acts specifically on the electrical signals in the heart to control the heart rhythm without significantly impacting other aspects of cardiovascular function.

Question 2

What is Ivabradine used for?

Accepted Answer

Ivabradine is used to treat heart failure .

Question 3

How does Ivabradine work?

Accepted Answer

Mechanism of Action

Ivabradine belongs to a class of medications called hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blockers. It works by targeting the sinoatrial node, which is the part of the heart that acts as a natural pacemaker to control the heart rate.

The medication works through the following process:

Targeting electrical currents: Ivabradine blocks a specific electrical current in the pacemaker cells of the heart. This current is responsible for starting each heartbeat.

Slowing the heart rate: By blocking this current, the medication increases the time between heartbeats, effectively slowing down the heart rate.

Improving heart function: When the heart beats more slowly, it has more time to fill with blood. This allows the heart to pump blood more efficiently throughout the body.

Ivabradine is unique because it lowers the heart rate without affecting the strength of the heart's contraction or significantly impacting blood pressure.

Question 4

What are the brand names for Ivabradine?

Accepted Answer

Ivabradine is sold under the brand name Corlanor .

Question 5

What are the active ingredients in Ivabradine?

Accepted Answer

The active ingredient in Ivabradine is ivabradine .

Question 6

What are the side effects of Ivabradine?

Accepted Answer

Common side effects of Ivabradine may include:

Bradycardia

Visual brightness

Fatigue

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Ivabradine?

Accepted Answer

Ivabradine belongs to the If channel inhibitor drug class.

Question 8

What is the dosage of Ivabradine and how do I take it?

Accepted Answer

How to Take Ivabradine

Ivabradine should be taken exactly as directed by a healthcare provider. It is usually taken twice a day with meals. Taking this medication with food helps the body absorb it properly.

Administration Instructions

Tablets: Swallow the tablets whole. Do not crush or chew them unless instructed otherwise by a doctor.

Oral Solution: If you are using the liquid form, use the specific oral syringe or measuring device provided with the medication to ensure the correct amount is taken. Do not use a household spoon to measure the dose.

Missed Dose

If a dose is missed, skip that dose and take the next scheduled dose at the regular time. Do not take extra medicine or double the dose to make up for a missed one.

Dietary Considerations

Avoid eating grapefruit or drinking grapefruit juice while taking ivabradine. Grapefruit can increase the levels of this medication in your blood, which may increase the risk of side effects.

Question 9

Is Ivabradine safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Ivabradine can cause fetal harm when taken during pregnancy. Research in animals has shown that the medication may lead to heart and skeletal birth defects. Because of these risks, healthcare providers typically advise against using ivabradine during pregnancy.

Individuals of reproductive potential should use effective contraception while taking this medication. If you suspect you are pregnant or plan to become pregnant, consult your healthcare provider to discuss alternative treatment options.

Breastfeeding

It is currently unknown if ivabradine is present in human breast milk. However, animal studies have demonstrated that the drug is excreted in milk. To avoid the risk of serious adverse reactions in a nursing infant, breastfeeding is generally not recommended during treatment with ivabradine. You should talk to your doctor about the risks and benefits of breastfeeding versus continuing the medication.

Question 10

What forms and strengths does Ivabradine come in?

Accepted Answer

Ivabradine is provided in the following oral formulations:

Film-coated tablets: These are solid tablets intended to be swallowed whole.

Oral solution: This is a liquid form of the medication, which may be used for pediatric patients or individuals who have difficulty swallowing solid tablets.

Question 11

What is the FDA approval status of Ivabradine?

Accepted Answer

FDA Approval and Indications

Ivabradine was first approved by the U.S. Food and Drug Administration (FDA) in April 2015. It is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure. Eligible patients must have a left ventricular ejection fraction (LVEF) of 35% or less, be in sinus rhythm with a resting heart rate of 70 beats per minute or higher, and be on the highest tolerated dose of beta-blockers or have a contraindication to them.

In April 2019, the FDA expanded the approved use to include pediatric patients aged 6 months and older who have stable symptomatic heart failure due to dilated cardiomyopathy.

Regulatory Status and Safety Information

Ivabradine is available only by prescription. It does not currently have a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) program. However, the FDA has monitored the drug for potential safety concerns since its release. In 2016, the FDA identified a potential signal of serious risk for bradycardia (slow heart rate) and atrial fibrillation based on reports in the FDA Adverse Event Reporting System (FAERS), which led to updated safety information in the drug's official labeling.

Question 12

What should I know about Ivabradine and fda approval?

Accepted Answer

Initial FDA Approval

The U.S. Food and Drug Administration (FDA) first approved ivabradine in April 2015. It was approved to reduce the risk of hospitalization in adults with stable, symptomatic chronic heart failure. This approval is specific to patients who have a left ventricular ejection fraction (a measure of how much blood the heart pumps out) of 35% or less. Additionally, patients must be in a normal heart rhythm (sinus rhythm) and have a resting heart rate of at least 70 beats per minute. The medication is intended for use in patients who are already taking the highest dose of beta-blockers they can tolerate or those who cannot take beta-blockers.

Pediatric Approval

In April 2019, the FDA expanded the approval of ivabradine to include children aged 6 months and older. It is used to treat stable symptomatic heart failure caused by dilated cardiomyopathy, a condition where the heart's main pumping chamber becomes enlarged and weakened. Like the adult indication, pediatric use requires the patient to be in sinus rhythm with an elevated heart rate.

Regulatory Classification

Ivabradine is the first medication in a class of drugs known as hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blockers. During its initial review, the FDA granted the drug priority review and fast-track status because it provided a new way to manage heart failure by slowing the heart rate without affecting blood pressure or the strength of the heart's contraction.

Ivabradine

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Fda Approval Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?